http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
NewLink Genetics to Participate in Upcoming Investor and Medical Conferences
-
NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
-
NewLink Genetics to Host Its First Quarter 2019 Conference Call on May 8, 2019
-
NewLink Genetics (NLNK) Reports Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
-
NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
-
NewLink Genetics Presents Encouraging Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019
-
NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
-
NewLink Genetics Announces Clinical Trial Abstract Presentation at AACR Annual Meeting
-
NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
-
NewLink Genetics Reports Fourth Quarter, Year-End 2018 Financial Results and Provides Update for Clinical Programs
-
NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
-
NewLink Genetics to Host Its Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019
-
NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
-
NewLink Genetics to Participate in the Immuno-Oncology 360° Conference
-
NewLink Genetics (NLNK) Announces Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML
-
NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
-
NewLink Genetics (NLNK) Says Merck (MRK) Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 to FDA
-
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
-
NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
-
NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumo
-
NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumo
-
NewLink Genetics (NLNK) Announces Publication of Abstracts for Presentation at SITC
-
NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
-
NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
-
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
-
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
-
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
-
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
-
NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
-
NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
-
NewLink Genetics to Participate in the Stifel 2018 Healthcare Conference
-
NewLink Genetics to Participate in the Stifel 2018 Healthcare Conference
-
NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018
-
NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018
-
NewLink Genetics Announces Indoximod Biomarker Data and Prodrug NLG802 Pharmacokinetic Data to be Presented at SITC 2018
-
NewLink Genetics Announces Indoximod Biomarker Data and Prodrug NLG802 Pharmacokinetic Data to be Presented at SITC 2018
-
NewLink Genetics to Participate in the Cantor Global Healthcare Conference
-
NewLink Genetics to Participate in the Cantor Global Healthcare Conference
-
NewLink Genetics to Participate in the Baird Global Healthcare Conference
-
NewLink Genetics to Participate in the Baird Global Healthcare Conference
-
NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance
-
NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash Guidance
-
NewLink Genetics to Host Its Second Quarter 2018 Financial Results Conference Call on July 31, 2018
-
NewLink Genetics to Host Its Second Quarter 2018 Financial Results Conference Call on July 31, 2018
-
NewLink Genetics (NLNK) Announces Positive Updated Phase 1 Data with Indoximod Plus Radio-Immunotherapy for Pediatric Patients with DIPG Presented
-
NewLink Genetics Announces Positive Updated Phase 1 Data with Indoximod Plus Radio-Immunotherapy for Pediatric Patients with DIPG Presented at ISPNO 2018
-
NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
-
NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
-
NewLink Genetics (NLNK) Highlights Final Results from Two Phase 2 Studies of Indoximod
-
NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018
